| Literature DB >> 33503407 |
Zhiqiang Huang1, Ning Liang1, Saioa Goñi1, Anastasios Damdimopoulos1, Cheng Wang2, Raphaelle Ballaire3, Jennifer Jager4, Henri Niskanen5, Hongya Han6, Tomas Jakobsson7, Adrian P Bracken2, Myriam Aouadi8, Nicolas Venteclef9, Minna U Kaikkonen5, Rongrong Fan10, Eckardt Treuter11.
Abstract
While the role of transcription factors and coactivators in controlling enhancer activity and chromatin structure linked to gene expression is well established, the involvement of corepressors is not. Using inflammatory macrophage activation as a model, we investigate here a corepressor complex containing GPS2 and SMRT both genome-wide and at the Ccl2 locus, encoding the chemokine CCL2 (MCP-1). We report that corepressors co-occupy candidate enhancers along with the coactivators CBP (H3K27 acetylase) and MED1 (mediator) but act antagonistically by repressing eRNA transcription-coupled H3K27 acetylation. Genome editing, transcriptional interference, and cistrome analysis reveals that apparently related enhancer and silencer elements control Ccl2 transcription in opposite ways. 4C-seq indicates that corepressor depletion or inflammatory signaling functions mechanistically similarly to trigger enhancer activation. In ob/ob mice, adipose tissue macrophage-selective depletion of the Ccl2 enhancer-transcribed eRNA reduces metaflammation. Thus, the identified corepressor-eRNA-chemokine pathway operates in vivo and suggests therapeutic opportunities by targeting eRNAs in immuno-metabolic diseases.Entities:
Keywords: GPS2; SMRT; chromatin remodeling; corepressor; eRNA; enhancer; epigenetics; inflammation; macrophage; silencer
Year: 2021 PMID: 33503407 DOI: 10.1016/j.molcel.2020.12.040
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970